The primary surgical indication was invasive ductal carcinoma, accounting for 50.8% of cases, followed by risk-reducing mastectomy in high-risk patients, including those with BRCA1/2 mutations, p53 carriers, and Li-Fraumeni syndrome, performed in 24.1% of patients. This evidence concerns the gene TP53 and invasive ductal breast carcinoma.